CONFERENCE DAY ONE
All times in EDT
7:30 am Registration Opens
8:45 am Chair’s Opening Remarks
9:00 am Panel Discussion: An Overview of the Hippo Pathway Drug Development Landscape
Synopsis
- What indications are showing most promise for therapeutic intervention on the Hippo pathway?
- Will targeted approaches on TEAD isoforms be the key to navigating risk of toxicity from pan-TEADs?
- How do we convince investors Hippo pathway treatments are worth their time when some consider the pathway ‘unvalidated’?
Mechanistic Insights into TEAD Palmitoylation to Deepen Functional Understanding of Inhibition
9:45 am Therapeutic Targeting of TEAD Transcription Factors in Cancer
Synopsis
- Understanding how YAP/TAZ-TEAD complex is activated in human cancer
- Demonstrating how TEAD hydrophobic pocket is druggable by small molecules
- Showcasing work on three covalent inhibitors targeting TEAD
10:15 am Update from Novartis on Lead Candidate
Synopsis
- Talk details TBC
10:45 am Morning Break & Speed Networking
11:45 am Leveraging NMR Fragment Screening Method to Identify Starting Points for Optimization & Disruption of the YAP/TAZ-TEAD Interaction to Develop Structurally Unique Lead-like Chemotypes for TEAD Inhibition
Synopsis
- Pinpointing the approach to develop a streamlined NMR screening platform to identify putative TEAD binders and hit assessment
- Showcasing a pipeline in structural science to allow X-ray structure determination of putative hit fragments
- Highlighting how mode of inhibition and kinetics of TEAD binders are defined based on crystallography and biophysical evaluation
Leveraging Biomarkers to Accelerate Established Hippo Pathway Clinical Drug Development
12:15 pm Biomarker-Guided Drug Development of YAP/TAZ-TEAD inhibitors
Synopsis
- SW-682: preclinical data for a novel TEAD inhibitor for Hippo-mutant cancers
- Overview of potential biomarkers for patient stratification, target engagement and molecular response
- Biomarkers for YAP activation as oncogenic driver or resistance mechanism to targeted therapies
12:45 pm Roundtable Discussion: Exploring What More Needs to be Done to Develop & Establish Hippo Pathway Biomarkers
Synopsis
- How can we better approach upstream hippo pathway biomarker discovery?
- Does inhibiting TEAD create a measurable functional effect on disease that could act as a biomarker?
- Are we selecting the right patients with the right TEAD isoform mutations?
- Are there biomarkers of resistance and how do we find them?
1:15 pm Lunch & Networking
2:15 pm Highlighting Alternatives: Novel Biomarkers for TEAD Selectivity
Synopsis
- Presenting preclinical updates on a lead covalent TEADi including in vivo efficacy
- Harnessing TEAD selectivity to expand into TEADi-responsive indications
- Exploring combination approaches with KRASi
2:45 pm Supercharging Hippo Pathway Clinical Drug Development with Clinical Insights into a TEAD Inhibitor
Synopsis
- Reviewing the preclinical in vivo data that has enabled translation into the clinic
- Presenting clinical efficacy data and insights into toxicology in a candidate TEAD inhibitor for a rare oncology indication
- Advancing drug development with plans for a phase 2
3:15 pm Afternoon Break & Networking
Broadening the Toolbox: Indications Showing Most Therapeutic Potential for Targeting the Hippo Pathway
3:45 pm Cardiovascular Conditions & the Hippo Pathway: Where’s the Potential?
Synopsis
- Assessing the data driving hippo pathway aberrations and incidence of cardiovascular conditions to spotlight the potential for drug development
- Characterizing cardio conditions and the existing treatment paradigm of disease
- Hypothesizing a logical approach to drug design to target hippo in cardio indications to inform translation
4:15 pm Championing TEAD Inhibitor in Combination to Tackle Resistance in Oncology
Synopsis
- Cataloging the preclinical in vivo data that has enabled translation into the clinic
- Exploring new data that points to mechanistic insights into Hippo pathway and cancer resistance
- Considering other potential pathways and drugs to use in combination
5:15 pm Chair’s Closing Remarks
5:30 pm End of Conference Day One
